Azitra, Inc. (NYSE American: AZTR) is a clinical-stage precision-dermatology biotech developing engineered proteins and topical live biotherapeutic products for skin diseases. Because the company is followed by essentially a single research firm, there is no meaningful multi-analyst consensus to average. The $4.00 objective is therefore treated as a public-discussion target, not an official consensus figure.
The figure comes from Maxim Group, whose analyst Jason McCarthy lowered the firm's price target on AZTR to $4.00 from $10.00 while maintaining a Buy rating in mid-November 2026. The $4.00 level is the most current, clearly attributed analyst price target available after the 1-for-10 reverse split took effect on October 26, 2026. Data aggregators show a wide and inconsistent range of published targets — roughly $1.00 to $6.50 — largely because several figures predate the reverse split or reflect stale inputs, making them unreliable for a current comparison. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
AZTR traded near $0.60 in mid-November 2026, with a market capitalization of only about $3.6 million. Reaching $4.00 from that level implies roughly a 567% upside, which must be described as a very large move. The company generates no product revenue, and its trailing EPS (earnings per share) was approximately -$2.80.
The stock's recent path has been shaped by the reverse split. The split briefly lifted shares to an intraday high around $2.13 on October 26 before the price faded through November, reflecting how speculative interest in the corporate action has outweighed near-term fundamentals. Any sustained climb toward $4.00 would likely require tangible clinical milestones rather than continued technical momentum.
The clearest supports are clinical. ATR-12 is in a Phase 1b trial for Netherton syndrome, a rare disease with no approved treatment, while ATR-04 for EGFR inhibitor-associated rash has FDA Fast Track designation and has advanced in its Phase 1/2 study. A newer cosmetic candidate, ATR-COSF, reported positive ex vivo data. If these programs produce positive safety and efficacy readouts, a higher valuation could become more defensible, and a reverse split that consolidates the share count may reduce the mechanical overhang of a sub-dollar price.
The obstacles are substantial. As a pre-revenue, cash-flow-negative biotech, AZTR depends on continued financing, and any equity raise would dilute existing holders. The company has faced NYSE American listing-compliance notices, and a 12-month exchange monitoring period adds uncertainty. Clinical-stage biotech also carries binary risk: disappointing trial data for ATR-12 or ATR-04 would likely pressure the stock sharply. Finally, the stock's micro-cap size makes it prone to outsized, sentiment-driven swings in both directions.
The 52-week range for AZTR was approximately $0.52 to $4.30, and the post-split intraday high near $2.13 from late October stands well above the current price. The $1.00 round-number level, equivalent to the pre-split $0.10 area, is a psychological marker the stock has struggled to hold. On the downside, the recent low near $0.52 is the clearest support reference. The $4.00 target sits above even the post-split peak, underscoring how far the objective is from the stock's current structure. From what I see, the post-split price action remains noisy and requires close monitoring.
Analyst price targets generally reflect a roughly 12-month research horizon, though Maxim's exact horizon was not specified publicly. The most important items to watch are clinical data updates for ATR-12 and ATR-04, any FDA regulatory feedback, financing announcements and dilution, compliance developments with the NYSE American, and any revision or withdrawal of the lone published target. Quarterly cash balances and burn rate will matter as much as trial headlines for a company of this size. I’m watching this closely for any updates on the pipeline.
The $4.00 target for AZTR is a single-firm, clearly attributed objective rather than a verified analyst consensus, and it implies a very large — roughly 567% — move from a price near $0.60. The case for reaching it rests almost entirely on clinical execution across ATR-12, ATR-04, and the cosmetic pipeline, while the case against it rests on a lack of revenue, cash constraints, dilution risk, and listing-compliance uncertainty. Coverage is too thin to reveal genuine analyst disagreement, and the post-reverse-split price history is short and noisy. Investors should treat the $4.00 figure as a directional reference rather than a forecast and focus on clinical readouts and financing developments before drawing conclusions.
In my own analysis, I frequently review Tickeron’s AI Daily Buy/Sell Signals to track shifts in technical behavior across volatile names. The platform uses artificial intelligence to monitor thousands of stocks and ETFs, issuing Buy, Sell, or Hold signals as conditions evolve. For a thinly traded micro-cap like AZTR, these signals offer an efficient way to spot changing trends alongside manual review. I find them helpful for complementing fundamental work on clinical-stage companies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +14.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTR advanced for three days, in 119 of 147 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
AZTR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for AZTR moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 9 similar instances where the indicator moved out of overbought territory. In 9 of the 9 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTR as a result. In 54 of 56 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AZTR turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 30 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
AZTR moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for AZTR entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. AZTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.053) is normal, around the industry mean (3.498). P/E Ratio (36.625) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (146.534) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology